Summary
The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647
combined with fludarabine and cyclophosphamide compared to fludarabine and
cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in
adults with relapsed or refractory large B-cell lymphoma